These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 18036728)

  • 1. Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
    Serati M; Salvatore S; Uccella S; Cromi A; Khullar V; Cardozo L; Bolis P
    Eur Urol; 2008 Oct; 54(4):911-5. PubMed ID: 18036728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?
    Serati M; Salvatore S; Uccella S; Cardozo L; Bolis P
    Eur Urol; 2009 Mar; 55(3):713-9. PubMed ID: 18584946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
    Kuo HC
    Eur Urol; 2008 Oct; 54(4):915-6. PubMed ID: 18036725
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
    Roumeguère T
    Eur Urol; 2008 Oct; 54(4):916-7. PubMed ID: 18036722
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of tolterodine in women with detrusor overactivity and anterior vaginal wall prolapse: is it the same?
    Salvatore S; Serati M; Ghezzi F; Uccella S; Cromi A; Bolis P
    BJOG; 2007 Nov; 114(11):1436-8. PubMed ID: 17877779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials.
    Nijman RJ; Borgstein NG; Ellsworth P; Djurhuus JC
    J Urol; 2005 Apr; 173(4):1334-9. PubMed ID: 15758796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG; Al-Buheissi S
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients.
    Michel MC; Oelke M; Goepel M; Beck E; Burkart M
    Neurourol Urodyn; 2007; 26(2):190-5. PubMed ID: 17096320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
    Choo MS; Doo CK; Lee KS
    Int J Clin Pract; 2008 Feb; 62(2):191-6. PubMed ID: 18067558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder.
    Watanabe M; Yamanishi T; Honda M; Sakakibara R; Uchiyama T; Yoshida K
    Int J Urol; 2010 Nov; 17(11):931-6. PubMed ID: 20969642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial.
    Elinoff V; Bavendam T; Glasser DB; Carlsson M; Eyland N; Roberts R
    Int J Clin Pract; 2006 Jun; 60(6):745-51. PubMed ID: 16805763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial.
    Roberts R; Bavendam T; Glasser DB; Carlsson M; Eyland N; Elinoff V
    Int J Clin Pract; 2006 Jun; 60(6):752-8. PubMed ID: 16805764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.
    Chu FM; Dmochowski RR; Lama DJ; Anderson RU; Sand PK
    Am J Obstet Gynecol; 2005 Jun; 192(6):1849-54; discussion 1854-5. PubMed ID: 15970828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolterodine extended-release for overactive bladder.
    Chung DE; Te AE
    Expert Opin Pharmacother; 2009 Sep; 10(13):2181-94. PubMed ID: 19663610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration.
    Wein AJ; Khullar V; Wang JT; Guan Z
    BJU Int; 2007 Feb; 99(2):360-3. PubMed ID: 17155987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.